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Abstract
Background: Surgical resection of liver metastases arising from colorectal cancer is considered
the only curative treatment option. However, many patients subsequently experience disease
recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of
recurrence following potentially curative liver resection. Special emphasis was directed to the
importance of response.
Methods:  50 patients with resectable liver metastases received neoadjuvant XELOX or
FOLFOX4 for six cycles (3 months). Complete resection of liver metastases was intended
thereafter. Assessments included response rate, postoperative morbidity and recurrence-free
survival.
Results: An objective response was observed in 72% of all patients, including two complete
responses. Chemotherapy was well tolerated and the majority of adverse events were mild to
moderate (grade 1/2). Potentially curative R0 resection was performed in all patients and
postoperative complications were observed in only 12%. The median recurrence-free survival was
significantly influenced by tumor response with 24.7 months (95% CI: 4.50 to 44.97) in responding
patients, 8.2 months (95% CI: 3.09 to 13.31) in patients with stable disease and 3.0 months (95%
CI: 0 to 8.91) in patients with progressive disease.
Conclusion: These data suggest that neoadjuvant Oxaliplatin based chemotherapy provides high
response rates without increased risk of perioperative morbidity. Response to chemotherapy can
lead to long-term recurrence-free survival. Neoadjuvant chemotherapy may identify best
candidates for a potentially curative treatment approach.
Background
Colorectal cancer is one of the most common malignan-
cies in the Western world [1]. The liver is a frequent site of
colorectal metastases, and 15% to 25% of patients have
liver metastases at diagnosis [2,3]. In addition, 50% to
60% of patients with localized disease at diagnosis even-
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tually develop advanced or metastatic disease. Median
survival of patients with metastatic colorectal cancer
treated with best supportive care alone is approximately 6
months [4]. The recent introduction of a number of new
promising anticancer agents, like irinotecan or oxaliplatin
in combination with 5-fluourocil, has resulted in
response rates of 40% to 50% and a median survival of 15
to 20 months [5-7].
Despite advances in survival with chemotherapy, surgical
resection of hepatic metastases is still considered the only
curative option for patients with liver metastases and no
extrahepatic disease, with 5-year survival rates after resec-
tion ranging from 25% to 45% [8,9]. However, even after
a successful resection, the majority of patients will experi-
ence disease recurrence[10]. The role of dormant cancer
cells, which subsequently will develop into metastases,
has been established in experimental models [11]. The
aim of systemic chemotherapy in patients with resectable
liver metastases is to eliminate these tumor cells and thus
reduce the risk of intrahepatic and extrahepatic recur-
rence. The majority of adjuvant studies in patients with
colorectal cancer following liver resection, which used
intra-arterial chemotherapy with or without systemic
treatment, have failed to demonstrate a survival benefit
[12-14].
Neoadjuvant chemotherapy appears promising, espe-
cially in patients with primarily resectable liver metastases
with high risk of early recurrence, using doublet chemo-
therapeutic regimens containing oxaliplatin or irinotecan
[15,16]. The intend of neoadjuvant chemotherapy is not
only to reduce the risk of recurrence and downsize the
liver metastases to enable less extensive surgery, but also
to identify a group of patients who may benefit most from
liver resection, namely the responders [17].
The aim of our prospective study was to determine the
efficacy of neoadjuvant chemotherapy consisting of oxali-
platin plus 5-FU/LV or capecitabine in potentially curable
patients with metastatic colorectal cancer and a high risk
of tumor recurrence. Feasibility of this treatment
approach has not been prospectively evaluated in terms of
the prolongation of recurrence-free survival time in
responding patients.
Methods
Patient selection
Patients were eligible for this prospective study if they had
histologically confirmed technically resectable colorectal
cancer liver metastases defined by a multidisciplinary
team including liver surgeons, radiologists and medical
oncologists, and at least one clinical risk factor for tumor
recurrence defined by Fong et al [8]. The liver metastases
had to be bidimensionally measurable, no limit in
number and location of the metastases was given as long
as they were defined resectable by the liver surgeon. In
addition, eligible patients were required to have the fol-
lowing characteristics: age 19 to 80 years; World Health
Organization (WHO) performance status of 0/1; ade-
quate bone marrow reserve adequate renal and hepatic
function.
Exclusion criteria were extrahepatic disease, prior pallia-
tive treatment, serious or uncontrolled concurrent medi-
cal illness and peripheral neuropathy (CTC > grade 1).
They were not allowed to participate in any other clinical
trial in the last 30 days. Written informed consent was
required from all patients prior to study entry. The study
was approved by the Institutional Review Board of the two
participating centers.
Treatment plan
Patients either received the standard FOLFOX4 regimen
consisting of 85 mg/m2 oxaliplatin (Eloxatin®; Sanofi-
Aventis, Collegeville, USA) administered on day 1 as a 2-
hours IV infusion; LV was given at the dose of 200 mg/
m2as a 2-hour IV infusion, followed by 5-FU 400 mg/m2
as IV bolus, and then, 600 mg/m2 as a 22-hour continuous
IV infusion, on days 1 and 2 or a XELOX regimen consist-
ing of oxaliplatin 130 mg/m2 administered as a 3-hour
infusion on day 1 plus capecitabine (Xeloda®) 2,000 mg/
m2/d po days 1 to 7 of a 2 week cycle.
Treatment courses were repeated every 2 weeks for a total
of six courses unless there was prior evidence of progres-
sive disease. Follow-up examinations including CT of the
chest and abdomen and tumor marker measurement were
carried out every 3 months during the first 2 years, every 6
months for the following 3 years and once yearly thereaf-
ter.
Allocation to FOLFOX4 or XELOX was based on institu-
tional preference of two oncology departments because
FOLFOX and XELOX were considered equally as first line
treatment of colorectal cancer.
Toxicity and dose modification guidelines
Adverse reactions were evaluated according to the
National Cancer Institute Common Toxicity Criteria
(NCI-CTC, Version 2.0) [18]. If patients experienced a
grade 4 hematological or ≥ grade 3 non-hematological
adverse event, the dose of chemotherapeutic drugs was
reduced by 25% for all subsequent doses. In addition, for
persistent severe neurotoxicity, despite a 25% dose reduc-
tion, oxaliplatin was temporarily withdrawn, with main-
tenance of 5-FU/LV or capecitabine, until recovery.
Treatment was delayed for up to 2 weeks if the absolute
neutrophil count was <1,500/µL or the platelet count was
<100,000/µL. Subcutaneous erythropoietin was recom-BMC Cancer 2008, 8:120 http://www.biomedcentral.com/1471-2407/8/120
Page 3 of 7
(page number not for citation purposes)
mended for patients with hemoglobin <10 g/dL. Patients
who required more than 2 weeks recovery from an adverse
reaction (> grad 1) were excluded from this protocol.
Pretreatment evaluations and assessment of response
Prior to therapy, all patients were assessed by physical
examination, routine hematology and biochemistry anal-
yses, and CT-scans of the thorax and abdomen to define
the extent of disease. Following the initial assessment,
complete blood cell counts and serum biochemistry anal-
yses were obtained at least once every course of treatment.
Carcinoembryonic antigen (CEA) levels were assessed
every 4 weeks. Subjective symptoms, physical examina-
tion results, performance status and all adverse reactions
were recorded before each treatment cycle according to
the CTC criteria [18]. Tumor size was measured after six
cycles by CT scan or MRI, and response rate was evaluated
according to RECIST criteria [19].
Statistical Analyses
The primary end point was response rate according to
RECIST criteria; secondary endpoints were resectability
rate and perioperative morbidity and mortality. The pro-
longation of overall and recurrence-free survival in
responding patients were additional secondary endpoints.
The study design to predict the number of patients neces-
sary for statistical validity (2-sided) was based on the
assumption that treatment with XELOX or FOLFOX
increases recurrence free survival time of responders com-
pared to patients who progressed on therapy by 10
months. Alpha was set at 0.05, beta at 0.2, yielding a
power of 80%; The calculated sample size for an acquisi-
tion period of 24 months and a follow up period of at
least 30 months was 38 patients.
The Kaplan-Meier method was used to estimate the
median overall survival and recurrence-free survival,
applying Log-Rang comparison. Uni- and multivariate
analyses and survival figures were plotted using SPSS for
Windows version 11.5.
Surgical technique
A CT-scan of the thorax and abdomen was performed at
the end of the sixth cycle of chemotherapy to exclude ext-
rahepatic disease. In addition, an echocardiogram, an
ECG, indocyanine green clearance and a lung function test
were performed routinely preoperatively. An intraopera-
tive ultrasonography was carried out to confirm the
number and size of metastases, to determine their rela-
tionship with vascular and biliary structures and for exclu-
sion of further intrahepatic metastases. Liver resection was
performed 2 to 5 weeks after the last administration of
chemotherapy, and all patients must have recovered from
any severe side effects of chemotherapy. Curative liver
resection was obligatory, which included the resection of
all liver metastases with a negative margin in a single pro-
cedure.
Results
Between May 2001 and November 2003, 50 patients with
colorectal cancer and resectable liver metastases were
included into this prospective, non-randomized trial.
Selected baseline demographics and disease characteris-
tics are shown in Table 1. The enrolled patients had a
median age of 62 (range 36 to77) years; metastases were
synchronous in 35 patients (70%) and metachronous
(diagnosed at least 6 months after the primary tumor) in
15 patients (30%). All patients received neoadjuvant
chemotherapy for 3 months with 30 (60%) and 20 (40%)
patients receiving XELOX and FOLFOX4, respectively.
Patient characteristics were similar between both groups.
Table 1: Patients characteristics
Parameter All patients (n = 50)
Age, median (range) 62 (36 to 77)
Sex (male/female) 34/16
ECOG performance status, n (0/1) 49/1
Disease stage, n (%)
M0/M1 15 (30)/35(70)
N0/N1,2 16 (32)/34 (68)
G1/2/3 7 (15)/41(81)/2 (4)
Number of metastatic lesions (%)
1 15 (30)
2–3 11 (22)
≥ 4 24 (48)
Lymph-node positive primary tumors, n (%) 34 (68)
Duration of metastatic disease < 12 months, n (%) 37 (74)
CEA > 20 ng/mL, n (%) 15 (30)
Synchronous metastases, n (%) 35 (70)
ECOG = Eastern Cooperative Oncology Group; CEA = carcinoembryonic antigenBMC Cancer 2008, 8:120 http://www.biomedcentral.com/1471-2407/8/120
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Toxicity
Hematological toxicity was observed in 27 (54%)
patients, which included one (2%) patient with grade 3
neutropenia and one (2%) patient with grade 4 thrombo-
cytopenia; all other hematological toxicities were mild to
moderate (grade 1 or 2). There were no episodes of febrile
neutropenia or bleeding. Non-hematological side effects
were reported in 33 (66%) patients (Table 2). The most
common mild to moderate (grade 1 or 2) non-hemato-
logical side effects were nausea (n = 17; 34%), diarrhea (n
= 6;12%), vomiting (n = 3; 6%), fatigue (n = 4; 8%),
peripheral neuropathy (n = 22; 44%) and hand-foot syn-
drome (n = 9; 18%). Grade 3 non-hematological side
effects were observed in 5 (10%) patients, including
diarrhea (n = 2; 4%), peripheral neuropathy (n = 2; 4%)
and vomiting (n = 1; 2%). No grade 4 non-hematological
side effects were observed.
The initial dose of capecitabine was reduced (25%) in two
patients receiving XELOX due to grade 3 diarrhea. A 25%
dose reduction of oxaliplatin was performed in two
patients, one each receiving XELOX and FOLFOX4, due to
grade 3 peripheral neuropathy. A dose reduction of both
agents was performed in two patients due to grade 4
thrombocytopenia (one XELOX patient) and grade 3
vomiting (one FOLFOX4 patient).
Response to chemotherapy
Tumor response was evaluated in all 50 patients. Only
two patients failed to receive all six cycles of chemother-
apy (one patient experienced progressive disease after
three cycles and the other patient discontinued after four
cycles due to personal reasons). An objective response was
observed in 36 (72%) patients (Table 3). Two (4%)
patients were reported radiologically to have a complete
response (CR); one was pathologically confirmed and via-
ble tumor cells were discovered during pathology in the
other patient; 34 (68%) patients had radiological con-
firmed partial response (PR). An additional 10 patients
(20%) demonstrated with stable disease (SD) and only
four patients (8%) had disease progression (PD). A reduc-
tion in CEA levels was observed in 63% of the patients,
whilst levels were unchanged in a further 19% of patients.
Tumor response was similar in patients who received
XELOX or FOLFOX4, respectively (complete/partial
response, 77% versus 65%; stable disease 13% versus
30%; progressive disease, 10% versus 5%).
Liver surgery, pathology, morbidity and mortality
R0 resection was performed in all 50 patients. Uniseg-
mental resections were performed in 10 (20%) patients,
bisegmentectomies were necessary in 13 (26%) patients
and 27 (54%) patients underwent major hepatectomies
(≥ 3 segments). Perioperative blood transfusions were
given to 16 (32%) patients, but only seven patients
required more than two units of packed red cells.
Postoperative complications were observed in only six
(12%) patients; two patients each experienced wound
healing problems, bilioma and an abscess formation.
There was no 60 day mortality and median duration of
hospitalization was 9 (range 5 to 29) days.
Recurrence-free and overall survival
The median duration of post-operative follow-up is 31
months (95% CI: 27.28 to 35.05). Recurrence of disease
was observed in 32 (64%) patients. The site of recurrence
was intrahepatic in 16 patients, extrahepatic in 10 patients
and both intra- and extrahepatic in 6 patients. There were
no marginal recurrences. The median duration of recur-
rence-free survival was 12.0 months. The duration of
median recurrence-free survival significantly differed
according to tumor response following neoadjuvant
chemotherapy, with 24.7 months (95% CI: 4.50 to 44.97)
in responding patients, 8.2 months (95% CI: 3.09 to
13.31) in patients with stable disease and 3.0 months
(95% CI: 0 to 8.91) in patients with progressive disease (p
< 0.004), Figure 1. Palliative chemotherapy was adminis-
tered to almost all patients with recurrent disease in the
different response categories (84% in PR/CR patients,
88% in SD pts and 100% in PD pts), surgery for recur-
rence was performed in one patient in each response
group and palliative care was given to two patients with
recurrence in the initially responding group.
The median overall survival has neither been reached in
responding patients nor in the entire population. In con-
trast, median overall survival in patients with stable dis-
ease was significantly longer than patients with
progressive disease (21.2 months [95% CI: 7.65 to 34.82]
vs 12.1 months [95% CI: 3.61 to 20.53]; p = 0.046). Mean
overall survival was 38 months (95% CI: 32.65 to 43.35).
Multivariate analyses revealed response to neoadjuvant
chemotherapy highly significant correlated to improved
Table 2: Selected adverse events
Adverse event Incidence (%)
Grade 1/2 Grade 3 Grade 4
Neutropenia 24 2 -
Anemia 46 - -
Thrombocytopenia 38 - 2
Nausea 34 0 -
Diarrhea 12 4 -
Vomiting 6 2 -
Fatigue 8 - -
Peripheral neuropathy 44 4 -
Hand-foot syndrome 18 - -BMC Cancer 2008, 8:120 http://www.biomedcentral.com/1471-2407/8/120
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recurrence-free survival (p = 0.002) and overall survival (p
= 0.017). Other factors in the RFS model were number of
metastases (p = 0.040), synchronous vs metachronous
metastases (p = 0.395) and lymph node status of the pri-
mary CRC (p = 0.243). All other factors in the model for
OS were negative: number of metastases (p = 0.732), time
of metastases (p = 0.642) and lymph nodes (p = 0.064).
Discussion
To date, resection of liver metastases in patients with
colorectal cancer is the only curative treatment option
[8,9]. However, the majority of patients develop recur-
rence following resection, either intra- or extrahepatically,
within 18 months after resection [20]. This may suggest
that many patients do not optimally benefit from surgery
and underlines that new treatment strategies are neces-
sary. Especially patients with multiple known risk factors
for early recurrence do certainly not benefit from a sole
surgical approach. According to Fong's risk factor defini-
tion the majority of the patients in our trial would qualify
for an overall survival of less than 30% after 5 years [8].
Available data, the published majority of which are from
retrospective studies, indicate that neoadjuvant chemo-
therapy is appropriate for the treatment of colorectal can-
cer liver metastases [21,22]. Neoadjuvant chemotherapy
has a number of potential benefits in patients with resect-
able liver metastases. These benefits include the potential
for improved selection of patients for resection by exclud-
ing patients who progress during neoadjuvant therapy, in
whom from our current knowledge surgery would be
inappropriate. Additionally, the response or tolerability to
a neoadjuvant chemotherapy regimen will help deter-
mine the optimal adjuvant chemotherapy. The beneficial
effect of the perioperative chemotherapy setting was
recently supported by the results of the EORTC 40983
study presented at the 2007 Annual Meeting of the Amer-
ican Association of Clinical Oncology [23]. Although a
high percentage of patients with a low recurrence risk pro-
file were randomized in this trial (e.g. over 50% pts with
a single liver metastasis) the analyses showed a significant
3 year recurrence-free survival benefit in eligible patients.
An objective response rate of 72%, including one patient
with complete pathological response, was observed in our
study. The decrease of tumor volume reduces the magni-
tude of liver resection whilst sparing normal hepatic tissue
and improves the complete resection rate. A significant
tumor response may also allow for easier resection and
improved postoperative recovery. In addition to the 72%
of patients who responded to neoadjuvant chemotherapy,
a further 20% of patients had stable disease. Even those
who progressed during neoadjuvant chemotherapy did
not become unresectable, however the usefulness of per-
forming liver resection in progressive patients is not sup-
ported by our results, because all these patients relapse
within 9 months after a potential curative approach.
In our study, a median recurrence-free survival of 12.0
months was observed with neoadjuvant XELOX or
FOLFOX4. Although patients have been followed for 31
months, median overall survival for all and responding
patients has not been reached; this is in contrast to those
Table 3: Analysis of efficacy
Efficacy measure All patients (n = 50)
Objective response, n (%) 36 (72)
Complete response 2 (4)
Partial response 34 (68)
Stable disease, n (%) 10 (20)
Progressive disease, n (%) 4 (8)
Mean overall survival, months (95% CI) 38.0 (32.65 to 43.35)
Median recurrence-free survival, responders; mts (95% CI) 24.73 (4.50 to 44.97)
Recurrence-free survival estimates; PR = partial response,  SD = stable disease, PD = progressive disease Figure 1
Recurrence-free survival estimates; PR = partial 
response, SD = stable disease, PD = progressive disease.BMC Cancer 2008, 8:120 http://www.biomedcentral.com/1471-2407/8/120
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who were stable or progressed under neoadjuvant chemo-
therapy. Interestingly, these findings may indicate that a
response to neoadjuvant chemotherapy may identify
patients with high long-term survival rates and those
appropriate for liver resection, and therefore potentially
curable. The significant difference identified for recur-
rence-free and overall survival if response to chemother-
apy occurs does support the value of neoadjuvant therapy
even in resectable patients.
A previous study of patients who received neoadjuvant
chemotherapy and surgery indicated that patients with
progressive disease had significantly worse 5-year survival
(8%) compared to patients with stable disease (30%) or
responsive disease (37%; p = 0.0001) [24]. Recurrence-
free survival and overall survival data from our study sup-
port these previous findings and may suggest that resec-
tion is appropriate only in responding and probably in
stable patients. These results add to the current discussion
of evaluating 2nd line treatment in progressive patients
prior to an optional surgical approach [25].
In an attempt to predict the survival of patients undergo-
ing liver resection, multivariate analyses have identified
factors predictive of recurrence or poor prognosis, includ-
ing primary disease stage, number and volume of metas-
tases and preoperative CEA concentration [8].
Neoadjuvant chemotherapy has at least in our study
improve these unfavorable prognostic factors in over two
third of the patients, and may therefore be considered an
ideal parameter to estimate prognosis in patients diag-
nosed with metastatic colorectal cancer. Response to treat-
ment positively influenced suspected worse prognosis
(according to a high Fong score) in our study group (data
not presented).
Phase II and III clinical trials have demonstrated that the
addition of bevacizumab to standard chemotherapy regi-
mens significantly improves response rates, overall sur-
vival and progression-free survival compared with
chemotherapy alone [26-28]. In addition, cetuximab
(Erbitux®) has demonstrated good response rates in previ-
ously treated patients with metastatic colorectal cancer
and recently proofed effective in the first line setting [29-
31]. Response rate is an important surrogate for neoadju-
vant therapy. Therefore, the encouraging response rates
produced with biological agents in combination with
chemotherapy suggest the potential for optimization of
neoadjuvant therapy. Studies evaluating the efficacy of
neoadjuvant therapy consisting of biological therapy are
ongoing and preliminary results are encouraging [32].
Advances in surgery including precise preoperative imag-
ing and control of intraoperative bleeding have improved
outcomes in the resection of colorectal liver metastases
[17]. A low rate of perioperative and postoperative com-
plications were observed in the present study. Similarly,
no cases of operative mortality were reported. These find-
ings are consistent with previous studies, indicating that
liver resection after neoadjuvant chemotherapy is feasible
without increased morbidity and mortality risk, particu-
larly in experienced hands [16,23,33].
Conclusion
We have shown that neoadjuvant chemotherapy in poten-
tially curable patients with metastatic colorectal cancer
and high risk of tumor recurrence using neoadjuvant
XELOX or FOLFOX4 provides high response rates that
allowed complete resection in all patients. The major
issue in the attempt to cure metastatic colorectal cancer,
the prolongation of recurrence-free survival was demon-
strated in responding patients in our study. In addition,
the chemotherapy regimens were well tolerated and low
rates of complications, morbidity and mortality were
observed. Although further studies are required to clarify
its potential role, neoadjuvant chemotherapy with XELOX
or FOLFOX4 should be considered as a valid treatment
option in patients with resectable colorectal cancer liver
metastases.
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